Stephen Willard
Vermögen: 609 669 $ am 31.05.2026
Vermögen: 609 669 $ am 31.05.2026
Stephen H.
Willard is currently Chief Executive Officer at Longeveron, Inc. since 2026.
Mr. Willard is also a Director at Global Life Technologies Corp.
and a Director at The National Science Board since 2018.
Formerly, Mr. Willard was Chief Executive Officer & Director at Cellphire, Inc. from 2013 to 2021, Chief Executive Officer & Secretary at NRX Pharmaceuticals, Inc. in 2024, Executive Director at Nozin, Inc. from 2021 to 2022, Non-Executive Chairman at Flamel Technologies SA from 2012 to 2014, Independent Director at E*TRADE Financial Corp.
from 2012 to 2014, Director at E*TRADE Bank from 2000 to 2014, Director at ETB Holdings, Inc. in 2005, Associate Director-Resolutions at Federal Deposit Insurance Corp.
from 1991 to 1994, Chief Executive Officer at Icapath, Inc., and President at Flamel Technologies, Inc. Education includes a graduate degree from Yale University conferred in 1985 and an undergraduate degree from Williams College conferred in 1982.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LONGEVERON INC. CLASS A 2,62 % | 01.05.2026 | 789.727 ( 2,62 % ) | 609 669 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LONGEVERON INC. | Vorstandsvorsitzender | 11.02.2026 |
Global Life Technologies Corp.
Global Life Technologies Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direktor/Vorstandsmitglied | - |
The National Science Board | Direktor/Vorstandsmitglied | 01.01.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
Icapath, Inc.
Icapath, Inc. Miscellaneous Commercial ServicesCommercial Services Develops drug delivery technology that combines PLGA nanoparticles | Vorstandsvorsitzender | 01.10.2025 |
| NRX PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 11.10.2024 |
Cellphire, Inc.
Cellphire, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that develops platelet-derived therapeutics | Vorstandsvorsitzender | 01.03.2021 |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Vorsitzender | 02.07.2014 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 14 |
|---|---|
E*TRADE Financial Corp.
E*TRADE Financial Corp. Investment Banks/BrokersFinance Provides online stock brokerage and investing services | Finance |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
E*TRADE Bank
E*TRADE Bank Regional BanksFinance Provides banking services | Finance |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Williams College
Williams College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Federal Deposit Insurance Corp.
Federal Deposit Insurance Corp. Insurance Brokers/ServicesFinance Operates as an insurance agency | Finance |
ETB Holdings, Inc.
ETB Holdings, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Flamel Technologies, Inc. | |
The National Science Board | |
Cellphire, Inc.
Cellphire, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that develops platelet-derived therapeutics | Commercial Services |
Longeveron, Inc.
Longeveron, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cellular therapies for aging-related and life-threatening conditions | Health Technology |
Global Life Technologies Corp.
Global Life Technologies Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
NRX Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a molecule pharmaceutical company | Health Technology |
Icapath, Inc.
Icapath, Inc. Miscellaneous Commercial ServicesCommercial Services Develops drug delivery technology that combines PLGA nanoparticles | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen